Logo image of DXCM

DEXCOM INC (DXCM) Stock Fundamental Analysis

USA - NASDAQ:DXCM - US2521311074 - Common Stock

75.58 USD
-0.64 (-0.84%)
Last: 9/15/2025, 8:00:02 PM
75.8 USD
+0.22 (+0.29%)
After Hours: 9/15/2025, 8:00:02 PM
Fundamental Rating

6

DXCM gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. DXCM has an excellent profitability rating, but there are some minor concerns on its financial health. DXCM is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, DXCM could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

DXCM had positive earnings in the past year.
DXCM had a positive operating cash flow in the past year.
In the past 5 years DXCM has always been profitable.
In the past 5 years DXCM always reported a positive cash flow from operatings.
DXCM Yearly Net Income VS EBIT VS OCF VS FCFDXCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

1.2 Ratios

DXCM has a Return On Assets of 7.80%. This is amongst the best in the industry. DXCM outperforms 90.05% of its industry peers.
DXCM has a Return On Equity of 22.21%. This is amongst the best in the industry. DXCM outperforms 94.24% of its industry peers.
DXCM has a Return On Invested Capital of 14.52%. This is amongst the best in the industry. DXCM outperforms 94.76% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DXCM is above the industry average of 8.46%.
The last Return On Invested Capital (14.52%) for DXCM is above the 3 year average (11.25%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.8%
ROE 22.21%
ROIC 14.52%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
DXCM Yearly ROA, ROE, ROICDXCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

The Profit Margin of DXCM (13.29%) is better than 89.01% of its industry peers.
In the last couple of years the Profit Margin of DXCM has grown nicely.
The Operating Margin of DXCM (17.22%) is better than 87.43% of its industry peers.
DXCM's Operating Margin has improved in the last couple of years.
DXCM's Gross Margin of 60.01% is fine compared to the rest of the industry. DXCM outperforms 60.73% of its industry peers.
DXCM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 17.22%
PM (TTM) 13.29%
GM 60.01%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
DXCM Yearly Profit, Operating, Gross MarginsDXCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

DXCM has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
DXCM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DXCM has been increased compared to 5 years ago.
DXCM has a better debt/assets ratio than last year.
DXCM Yearly Shares OutstandingDXCM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
DXCM Yearly Total Debt VS Total AssetsDXCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 5.30 indicates that DXCM is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.30, DXCM belongs to the best of the industry, outperforming 80.63% of the companies in the same industry.
The Debt to FCF ratio of DXCM is 4.38, which is a neutral value as it means it would take DXCM, 4.38 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DXCM (4.38) is better than 81.68% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that DXCM is somewhat dependend on debt financing.
DXCM has a worse Debt to Equity ratio (0.50) than 60.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 4.38
Altman-Z 5.3
ROIC/WACC1.8
WACC8.05%
DXCM Yearly LT Debt VS Equity VS FCFDXCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 1.52 indicates that DXCM should not have too much problems paying its short term obligations.
DXCM has a worse Current ratio (1.52) than 73.82% of its industry peers.
A Quick Ratio of 1.35 indicates that DXCM should not have too much problems paying its short term obligations.
The Quick ratio of DXCM (1.35) is worse than 63.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.35
DXCM Yearly Current Assets VS Current LiabilitesDXCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

7

3. Growth

3.1 Past

The earnings per share for DXCM have decreased by -2.86% in the last year.
The Earnings Per Share has been growing by 29.25% on average over the past years. This is a very strong growth
DXCM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.30%.
DXCM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.27% yearly.
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%

3.2 Future

DXCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.00% yearly.
Based on estimates for the next years, DXCM will show a quite strong growth in Revenue. The Revenue will grow by 14.08% on average per year.
EPS Next Y26.67%
EPS Next 2Y25.95%
EPS Next 3Y24.52%
EPS Next 5Y23%
Revenue Next Year15.01%
Revenue Next 2Y15.3%
Revenue Next 3Y14.97%
Revenue Next 5Y14.08%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DXCM Yearly Revenue VS EstimatesDXCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
DXCM Yearly EPS VS EstimatesDXCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4 5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 44.46, which means the current valuation is very expensive for DXCM.
Based on the Price/Earnings ratio, DXCM is valued a bit cheaper than the industry average as 69.63% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.27, DXCM is valued quite expensively.
A Price/Forward Earnings ratio of 28.88 indicates a quite expensive valuation of DXCM.
Based on the Price/Forward Earnings ratio, DXCM is valued a bit cheaper than the industry average as 72.77% of the companies are valued more expensively.
DXCM is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.77, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 44.46
Fwd PE 28.88
DXCM Price Earnings VS Forward Price EarningsDXCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, DXCM is valued a bit cheaper than the industry average as 71.73% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, DXCM is valued a bit cheaper than 76.44% of the companies in the same industry.
Industry RankSector Rank
P/FCF 51.93
EV/EBITDA 28.09
DXCM Per share dataDXCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
DXCM has an outstanding profitability rating, which may justify a higher PE ratio.
DXCM's earnings are expected to grow with 24.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.67
PEG (5Y)1.52
EPS Next 2Y25.95%
EPS Next 3Y24.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DXCM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DEXCOM INC

NASDAQ:DXCM (9/15/2025, 8:00:02 PM)

After market: 75.8 +0.22 (+0.29%)

75.58

-0.64 (-0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-22 2025-10-22/amc
Inst Owners97.5%
Inst Owner Change0.88%
Ins Owners0.26%
Ins Owner Change2.45%
Market Cap29.64B
Analysts85.71
Price Target105.4 (39.45%)
Short Float %2.54%
Short Ratio2.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.34%
Min EPS beat(2)-4.09%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-1.87%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)9.43%
EPS beat(12)10
Avg EPS beat(12)14.38%
EPS beat(16)11
Avg EPS beat(16)8.49%
Revenue beat(2)1
Avg Revenue beat(2)0.34%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-1.66%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.78%
Revenue beat(12)5
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-0.42%
PT rev (1m)-0.08%
PT rev (3m)3.61%
EPS NQ rev (1m)-0.05%
EPS NQ rev (3m)0.2%
EPS NY rev (1m)0.93%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)0.67%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)0.25%
Valuation
Industry RankSector Rank
PE 44.46
Fwd PE 28.88
P/S 6.89
P/FCF 51.93
P/OCF 30.01
P/B 11.52
P/tB 12.04
EV/EBITDA 28.09
EPS(TTM)1.7
EY2.25%
EPS(NY)2.62
Fwd EY3.46%
FCF(TTM)1.46
FCFY1.93%
OCF(TTM)2.52
OCFY3.33%
SpS10.97
BVpS6.56
TBVpS6.28
PEG (NY)1.67
PEG (5Y)1.52
Profitability
Industry RankSector Rank
ROA 7.8%
ROE 22.21%
ROCE 18.43%
ROIC 14.52%
ROICexc 53.56%
ROICexgc 59.66%
OM 17.22%
PM (TTM) 13.29%
GM 60.01%
FCFM 13.27%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexcg growth 3Y55.18%
ROICexcg growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 4.38
Debt/EBITDA 1.33
Cap/Depr 176.58%
Cap/Sales 9.69%
Interest Coverage 250
Cash Conversion 101.12%
Profit Quality 99.88%
Current Ratio 1.52
Quick Ratio 1.35
Altman-Z 5.3
F-Score6
WACC8.05%
ROIC/WACC1.8
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
EPS Next Y26.67%
EPS Next 2Y25.95%
EPS Next 3Y24.52%
EPS Next 5Y23%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
Revenue Next Year15.01%
Revenue Next 2Y15.3%
Revenue Next 3Y14.97%
Revenue Next 5Y14.08%
EBIT growth 1Y6.1%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year76.6%
EBIT Next 3Y38.89%
EBIT Next 5Y31.85%
FCF growth 1Y22.49%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y28.04%
OCF growth 3Y30.77%
OCF growth 5Y25.76%